Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8532779 | Journal of Pharmacological Sciences | 2018 | 4 Pages |
Abstract
We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin-angiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD). Oral administration of the selective SGLT2 inhibitor, TA-1887 (10Â mg/kg/day), for 10 weeks induced glycosuria. However, plasma renin activity, plasma angiotensinogen levels, kidney angiotensin II contents and renal injury were not significantly affected by TA-1887. These data indicate that chronic treatment with an SGLT2 inhibitor does not activate the systemic and intrarenal RAS in subjects with non-diabetic CKD.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Lei Li, Yoshio Konishi, Takashi Morikawa, Yifan Zhang, Chizuko Kitabayashi, Hideki Kobara, Tsutomu Masaki, Daisuke Nakano, Hirofumi Hitomi, Hiroyuki Kobori, Akira Nishiyama,